Cardiorostin FB Tablet - Strip of 10

• Cardiorostin FB Tablet provides comprehensive lipid control by effectively lowering LDL-C and triglycerides while raising HDL-C.
• This formulation is particularly beneficial for patients with mixed dyslipidemia, addressing multiple lipid abnormalities simultaneously.
• Enhanced cardiovascular protection is achieved through the combined action of Rosuvastatin and Fenofibrate, reducing atherogenic particles.
• Cardiorostin FB Tablet simplifies treatment regimens, improving patient adherence by consolidating multiple medications into one daily tablet.
• The medication helps prevent complications associated with dyslipidemia, such as heart attacks and strokes.
• Regular use of Cardiorostin FB Tablet can lead to significant improvements in overall cardiovascular health.
• This therapy is suitable for long-term management of dyslipidemia, ensuring sustained lipid control.
• Cardiorostin FB Tablet is effective in patients who have not achieved desired lipid levels with statin monotherapy alone.

Cardiorostin FB Tablet combines two powerful lipid-lowering agents: Rosuvastatin and Fenofibrate. Together, they work synergistically to improve lipid profiles by lowering bad cholesterol (LDL) and triglycerides while increasing good cholesterol (HDL).

• Rosuvastatin inhibits HMG-CoA reductase, reducing cholesterol synthesis in the liver.
• This inhibition leads to increased hepatic LDL receptor activity, enhancing clearance of LDL-C from the bloodstream.
• Fenofibrate activates PPARα, promoting fatty acid oxidation and reducing triglyceride levels.
• By decreasing ApoC-III expression, Fenofibrate enhances lipoprotein lipase activity, further lowering triglyceride levels.
• Both components work together to normalize lipid levels effectively, reducing cardiovascular risk.
• The combination therapy provided by Cardiorostin FB Tablet is more effective than either drug alone in managing mixed dyslipidemia.

• Take one Cardiorostin FB Tablet daily as prescribed by your healthcare provider.
• The tablet can be taken at any time of day; consistency is key for optimal results.
• Swallow the tablet whole with water; it can be taken with or without food.
• Regular monitoring of lipid levels and liver function tests is essential during treatment with Cardiorostin FB Tablet.
• Do not alter the dosage without consulting your doctor; this is a long-term therapy.
• If you miss a dose, take it as soon as you remember within 12 hours; otherwise, skip it and resume your regular schedule.
• Consult your healthcare provider before stopping the medication, even if you feel better.
• Ensure regular follow-ups to assess treatment efficacy and safety.

• Maintain a heart-healthy diet rich in fruits, vegetables, whole grains, and lean proteins while on Cardiorostin FB Tablet.
• Avoid high-fat and high-cholesterol foods to enhance the effectiveness of this therapy.
• Engage in regular physical activity to support cardiovascular health and weight management.
• Avoid smoking and limit alcohol intake to reduce cardiovascular risks associated with dyslipidemia.
• Stay hydrated and manage stress through relaxation techniques or exercise to support overall well-being while on treatment.

• Common side effects include headache, dizziness, nausea, abdominal pain, constipation, and diarrhea.
• Muscle pain or weakness may occur; report any unexplained muscle symptoms to your doctor immediately.
• Mild elevation of liver enzymes (ALT/AST) may be observed; regular monitoring is advised.
• Serious side effects include severe muscle symptoms (rhabdomyolysis), requiring urgent medical attention if experienced.
• Signs of liver damage such as jaundice or persistent nausea should prompt immediate consultation with a healthcare provider.
• Gallstones may develop; seek medical advice if experiencing severe abdominal pain.

• Cardiorostin FB Tablet is contraindicated in patients with active liver disease or unexplained elevated liver enzymes.
• Caution is advised for individuals with kidney disease; dose adjustments may be necessary.
• Avoid alcohol consumption while taking Cardiorostin FB Tablet due to increased risk of liver damage.
• This medication is not recommended during pregnancy due to potential harm to the fetus; consult your doctor for alternatives.
• Breastfeeding mothers should seek medical advice before using Cardiorostin FB Tablet as it may pass into breast milk.
• Patients should inform their healthcare provider about any history of myopathy or rhabdomyolysis before starting treatment.